Assessment of Eculizumab and C5 Levels in PNH Treatment: Molar Ratio of Eculizumab to C5 Level Effectively Predicts Ongoing Dosage Changes in a Cohort of 50 Patients Treated with Eculizumab

Newton, DJ, McKinley, CE, Ricardo, A et al. (8 more authors) (2017) Assessment of Eculizumab and C5 Levels in PNH Treatment: Molar Ratio of Eculizumab to C5 Level Effectively Predicts Ongoing Dosage Changes in a Cohort of 50 Patients Treated with Eculizumab. In: 59th ASH Annual Meeting Abstracts, 09-12 Dec 2017, Atlanta, GA, USA.

Metadata

Item Type: Conference or Workshop Item
Authors/Creators:
  • Newton, DJ
  • McKinley, CE
  • Ricardo, A
  • Hoarty, MD
  • Arnold, L
  • Riley, K
  • Copeland, N
  • Munir, T
  • Griffin, M
  • Hill, A
  • Hillmen, P
Dates:
  • Published: 7 December 2017
Institution: The University of Leeds
Depositing User: Symplectic Publications
Date Deposited: 06 Jan 2022 16:58
Last Modified: 06 Jan 2022 16:58
Status: Published
Identification Number: 10.1182/blood.V130.Suppl_1.3484.3484
Related URLs:
Open Archives Initiative ID (OAI ID):

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Export

Statistics


CORE (COnnecting REpositories)